
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9127131/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The use of remote monitoring of cardiac implantable devices during the COVID-19 pandemic: an EHRA physician survey. Europace, 2022, 24, 473-480.	1.7	32
2	Assessment of the need of a waiting period after pulmonary vein isolation with the ablation index software. Journal of Cardiovascular Electrophysiology, 2022, 33, 1725-1733.	1.7	4
3	Anticoagulation in atrial fibrillation. Heart, 2021, 107, 419-427.	2.9	9

Non-vitamin K antagonist oral anticoagulation versus left atrial appendage occlusion for primary and secondary stroke prevention after cardioembolic stroke, Revista Portuguesa De Cardiologia (English) Ti ETO 0.0.0 (Cardiologia (English) (Cardiologia

4	secondary stroke prevention after cardioembolic stroke. Revista Portuguesa De Cardiologia (English) Tj ETQq0 C	0 ng:BT/C	verbock 107
5	Non-vitamin K antagonist oral anticoagulation versus left atrial appendage occlusion for primary and secondary stroke prevention after cardioembolic stroke. Revista Portuguesa De Cardiologia, 2021, 40, 357-365.	0.5	9
6	Impact of catheter ablation for atrial fibrillation in patients with heart failure and left ventricular systolic dysfunction. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 437-444.	0.2	2
7	Pattern Matching Filter and multielectrode mapping catheter – A new approach for complex premature ventricular contraction ablation. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 423-431.	0.2	1
8	Effectiveness and safety of a single freeze strategy of cryoballoon ablation of atrial fibrillation: an EHRA systematic review and meta-analysis. Europace, 2021, , .	1.7	9
9	Extended early meets late for assessment of conduction block along an ablation line. Journal of Interventional Cardiac Electrophysiology, 2021, , 1.	1.3	0
10	Long-Term Impact of Body Mass Index on Survival of Patients Undergoing Cardiac Resynchronization Therapy: A Multi-Centre Study. American Journal of Cardiology, 2021, 153, 79-85.	1.6	0
11	Time to revisit implantable cardioverter-defibrillator implantation criteria in women. European Heart Journal, 2021, 42, 1110-1112.	2.2	3
12	Mapeamento com Software Coherent para Ablação de Flutter Atrial AtÃpico – Um Passo à Frente na Compreensão do Mecanismo da Arritmia. Arquivos Brasileiros De Cardiologia, 2021, 117, 1212-1216.	0.8	0
13	HD Coloring for atypical atrial flutter after mitral valve repair: What is the mechanism?. Journal of Cardiovascular Electrophysiology, 2020, 31, 252-255.	1.7	4
14	Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review. European Heart Journal, 2020, 41, 1976-1986.	2.2	33
15	latrogenic bradyarrhythmia: A benign phenomenon?. Revista Portuguesa De Cardiologia, 2019, 38, 113-115.	0.5	0
16	Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Archives of Cardiovascular Diseases, 2019, 112, 523-531.	1.6	1
17	Atrial Fibrillation Ablation and Reduction of Stroke Events. Stroke, 2019, 50, 2970-2976.	2.0	14
18	Full blood count as potential predictor of outcomes in patients undergoing cardiac resynchronization therapy. Scientific Reports, 2019, 9, 13016.	3.3	4

#	Article	IF	CITATIONS
19	HD Coloring for assessment of block along an ablation line. Journal of Cardiovascular Electrophysiology, 2019, 30, 1692-1693.	1.7	4
20	Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. European Heart Journal, 2019, 40, 2121-2127.	2.2	29
21	latrogenic bradyarrhythmia: A benign phenomenon?. Revista Portuguesa De Cardiologia (English) Tj ETQq1 1 0.75	84314 rgB 0.2	T /Overlock
22	Standardizing atrial fibrillation ablation with the cryoballoon: A song of ice versus fire?. Revista Portuguesa De Cardiologia, 2019, 38, 845-846.	0.5	0
23	Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. International Journal of Cardiology, 2018, 262, 51-56.	1.7	17
24	Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention. Heart, 2018, 104, 1529-1535.	2.9	20
25	Patients upgraded to cardiac resynchronization therapy due to pacing-induced cardiomyopathy are at low risk of life-threatening ventricular arrhythmias: a long-term cause-of-death analysis. Europace, 2018, 20, 89-96.	1.7	14
26	Cause-of-death analysis in patients with cardiac resynchronization therapy with or without a defibrillator: a systematic review and proportional meta-analysis. Europace, 2018, 20, 481-491.	1.7	15
27	Do women benefit equally as men from the primary prevention implantable cardioverter-defibrillator?. Europace, 2018, 20, 897-901.	1.7	28
28	Premature Ventricular Complex-induced Cardiomyopathy. Arrhythmia and Electrophysiology Review, 2018, 7, 128.	2.4	36
29	Acute and sub-acute sinus node dysfunction following pulmonary vein isolation: a case series. European Heart Journal - Case Reports, 2018, 2, ytx020.	0.6	7
30	Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review and meta-analysis. International Journal of Cardiology, 2018, 266, 136-142.	1.7	32
31	An individualized left ventricular lead-targeting strategy improves long-term survival of cardiac resynchronization therapy patients and influences the benefit of the implantable cardioverter-defibrillator. Journal of Cardiovascular Medicine, 2017, 18, 553-555.	1.5	0
32	Sex-specific outcomes with addition of defibrillation to resynchronisation therapy in patients with heart failure. Heart, 2017, 103, 753-760.	2.9	21
33	Adding Defibrillation Therapy to CardiacÂResynchronization on the BasisÂofÂthe MyocardialÂSubstrate. Journal of the American College of Cardiology, 2017, 69, 1669-1678.	2.8	56
34	Risk stratification in acute coronary syndromes: Graced by a new score?. Revista Portuguesa De Cardiologia, 2017, 36, 677-679.	0.5	2
35	The Benefit of Cardiac Resynchronization TherapyÂlsÂNot Hindered by the Number of Comorbidities. Journal of the American College of Cardiology, 2017, 70, 2096-2097.	2.8	4
36	Dualâ€site right ventricular pacing in patients undergoing cardiac resynchronization therapy: Results of a multicenter propensityâ€matched analysis. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1113-1120.	1.2	1

#	Article	IF	CITATIONS
37	Impact of an Age-Adjusted Co-morbidity Index on Survival of Patients With Heart Failure Implanted With Cardiac Resynchronization Therapy Devices. American Journal of Cardiology, 2017, 120, 1158-1165.	1.6	12
38	Atrial fibrillation monitoring to reduce thromboembolic risk: Selecting the patient and the monitoring device. Revista Portuguesa De Cardiologia, 2017, 36, 547-549.	0.5	0
39	Atrial fibrillation monitoring to reduce thromboembolic risk: Selecting the patient and the monitoring device. Revista Portuguesa De Cardiologia (English Edition), 2017, 36, 547-549.	0.2	Ο
40	Comparison of Three Criteria for Interpretation of Electrocardiogram in the Military. Military Medicine, 2017, 182, e2041-e2045.	0.8	1
41	Outcome of Primary Prevention Implantable Cardioverter Defibrillator Therapy According to New York Heart Association Functional Classification. American Journal of Cardiology, 2016, 118, 1225-1232.	1.6	8
42	Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. Europace, 2016, 18, 1187-1193.	1.7	25
43	Implantable cardioverter-defibrillator elective generator replacement: a procedure for all?. Journal of Interventional Cardiac Electrophysiology, 2016, 45, 209-218.	1.3	6
44	Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients?. International Journal of Cardiology, 2016, 203, 184-186.	1.7	2
45	Estimating glomerular filtration rate in acute coronary syndromes: Different equations, different mortality risk prediction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 223-230.	1.0	14
46	Authors' reply. Europace, 2015, 17, 1456-1456.	1.7	0
47	Letter by Barra et al Regarding Article, "REPLACE DARE (Death After Replacement Evaluation) Score: Determinants of All-Cause Mortality After Implantable Device Replacement or Upgrade From the REPLACE Registry― Circulation: Arrhythmia and Electrophysiology, 2015, 8, 513-513.	4.8	1
48	Is atrial fibrillation so common after supraventricular arrhythmia ablation as to require prophylactic treatment?. Europace, 2015, 17, 1-2.	1.7	116
49	Untreated atrial fibrillation in the United Kingdom: Understanding the barriers and treatment options. Journal of the Saudi Heart Association, 2015, 27, 31-43.	0.4	15
50	Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace, 2015, 17, 174-186.	1.7	64
51	Bundle Branch Reentry Beats, Hisian Ectopics, or Dual AV Nodal Physiology? Ablating to Achieve 100% Biventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 768-771.	1.2	2
52	Cardioverter-defibrillator implantation and generator replacement in the octogenarian. Europace, 2015, 17, 409-416.	1.7	23
53	Cardiac resynchronization therapy defibrillator at the end of battery life: In an era of economic uncertainty, do super-responders provide an opportunity for resource optimization?. International Journal of Cardiology, 2015, 199, 384-385.	1.7	1
54	Importance of Implantable Cardioverterâ€Đefibrillator Backâ€Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2015, 4, .	3.7	28

#	Article	IF	CITATIONS
55	Ablation of Ventricular Tachycardia in the Very Elderly Patient With Cardiomyopathy: How Old Is Too Old?. Canadian Journal of Cardiology, 2015, 31, 717-722.	1.7	14
56	Letter by Barra and Agarwal Regarding Article, "Survival After Implantable Cardioverter-Defibrillator Implantation in the Elderly― Circulation, 2014, 129, e336.	1.6	0
57	Pulmonary embolism risk stratification: where are we heading?. European Respiratory Journal, 2014, 43, 298-300.	6.7	2
58	Post-acute management of the acquired long QT syndrome. Postgraduate Medical Journal, 2014, 90, 348-358.	1.8	17
59	SÃndrome cardiorrenal na insuficiência cardÃaca aguda: um cÃrculo vicioso?. Revista Portuguesa De Cardiologia, 2014, 33, 139-146.	0.5	10
60	Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 2014, 114, 646-653.	1.6	63
61	Contrast-enhanced multidetector computed tomography: A new prognosticator in acute pulmonary embolism?. Revista Portuguesa De Cardiologia, 2013, 32, 839-840.	0.5	Ο
62	Contrast-enhanced multidetector computed tomography: A new prognosticator in acute pulmonary embolism?. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 839-840.	0.2	0
63	The Role of Echocardiography in Thromboembolic Risk Assessment of Patients with Nonvalvular Atrial Fibrillation. Journal of the American Society of Echocardiography, 2013, 26, 801-812.	2.8	35
64	Early Repolarization and Arrhythmia Death. Journal of the American College of Cardiology, 2013, 61, 2315-2316.	2.8	0
65	Incessant slow bundle branch reentrant ventricular tachycardia in a young patient with left ventricular noncompaction. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 523-529.	0.2	9
66	Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thrombosis Research, 2013, 132, 293-299.	1.7	30
67	Incessant slow bundle branch reentrant ventricular tachycardia in a young patient with left ventricular noncompaction. Revista Portuguesa De Cardiologia, 2013, 32, 523-529.	0.5	11
68	Decreased Glomerular Filtration Rate and Markers of Left Atrial Stasis in Patients with Nonvalvular Atrial Fibrillation. Cardiology, 2013, 124, 3-10.	1.4	31
69	Fever outperforms flecainide test in the unmasking of type 1 Brugada syndrome electrocardiogram. Europace, 2013, 15, 394-394.	1.7	15
70	Early repolarization patterns and the role of additional proarrhythmic triggers. Europace, 2013, 15, 482-485.	1.7	13
71	Performance of the Cockcroft-Gault, MDRD and CKD-EPI Formulae in Non-Valvular Atrial Fibrillation: Which one Should be Used for Risk Stratification?. Journal of Atrial Fibrillation, 2013, 6, 896.	0.5	4
72	Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS. Journal of Atrial Fibrillation, 2013, 6, 897.	0.5	0

#	Article	IF	CITATIONS
73	ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 320-336.	1.0	9
74	Mitral regurgitation during a myocardial infarction – New predictors and prognostic significance at two years of follow-up. Acute Cardiac Care, 2012, 14, 27-33.	0.2	7
75	Glomerular filtration rate: Which formula should be used in patients with myocardial infarction?. Revista Portuguesa De Cardiologia (English Edition), 2012, 31, 493-502.	0.2	5

76 Hypertension in pregnancy: The current state of the art. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

77	LR–PED Rule: Low Risk Pulmonary Embolism Decision Rule – A new decision score for low risk Pulmonary Embolism. Thrombosis Research, 2012, 130, 327-333.	1.7	26
78	Challenging pulmonary embolism - A new generation of oral anticoagulants. Journal of Thoracic Disease, 2012, 4, 244-6.	1.4	2
79	The Role of Echocardiography as a Predictor of the Incidence and Progression of Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 713.	0.5	2
80	Voluminous fistula between the right coronary artery and a branch of the pulmonary artery causing myocardial ischemia. Journal of Invasive Cardiology, 2012, 24, E139-41.	0.4	0
81	Prediction of cerebrovascular event risk following myocardial infarction. Revista Portuguesa De Cardiologia (English Edition), 2011, 30, 655-663.	0.2	3